Ness Ziona-based biotech firm Kadimastem has shown encouraging results of Cohort B of its Phase 1/2a clinical trial for AstroRx, its Amyotrophic Lateral Sclerosis (ALS) treatment trial. The objective of this trial was to evaluate the safety of their treatment, with a secondary objective of the trial of estimating its preliminary efficacy. The treatment was developed by Kadimastem and contains functional, healthy astrocytes (nervous system support cells) derived from Human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons Continue reading →

NEW YORK, Dec. Continue reading →

The ALS Treatment Market research report helps the market players to execute phenomenal business techniques and therefore, it has featured driving contenders vital moves including acquisitions, business extension, mergers, joint efforts, adventures, limited time exercises, branding, and product dispatches. The SWOT analysis incorporates inner and outside variables, just as present and future capability of the market. Continue reading →

December 16, 2020 11:55 ET | Source: AB Science multilang-release AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY DECEMBER 17, 2020 ON MASITINIB RESULTS IN ALZHEIMERS DISEASE Paris, December 16, 2020, 6pm CET AB Science SA (NYSE Euronext FR0010557264 AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimers Disease. Continue reading →

December 16, 2020 15:46 ET | Source: Stephen Siller Tunnel To Towers Foundation photo-release Staten Island, NY, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The Tunnel to Towers Foundation and The Home Depot Foundation today announced that they have teamed up to provide financial assistance to three of our nations veterans this holiday season. Continue reading →